What was recalled
The U.S. Food and Drug Administration (FDA) has issued a Class II recall for a specific pharmaceutical ingredient distributed by Shoolin Pharma Chem LLP. This is not a finished consumer medication that you would typically pick up at a pharmacy counter, but rather a raw active pharmaceutical ingredient intended for professional use. The product in question is Tadalafil USP, supplied in 0.100 KG (or 100-gram) bags. The packaging clearly designates the contents as "Rx only" and explicitly states that it is "For Prescription Compounding Only." This distinction is critical because it indicates that this chemical powder is meant to be processed by pharmacists or compounding specialists to create customized medications for individual patients, rather than being sold directly to the general public for immediate use.
The specific batch affected by this recall is identified by Lot number TLF2506001. Consumers and healthcare providers should note that the expiry date for this lot is May 31, 2028, which means the product was well within its shelf life at the time of distribution. The National Drug Code (NDC) associated with this recalled item is 85702-002-02. While the chemical identity is standard Tadalafil USP, identified by CAS number 1715996-29-5, the source and manufacturing process are under scrutiny. Shoolin Pharma Chem LLP is located in Gujarat, India, specifically at Block/Survey no 408, B/H Ratnamani Tubes, Near Maruti Inox, Indrad, Kadi, Mahesania, 382715.
The scope of this recall is significant due to its distribution pattern. The recalled Tadalafil was distributed nationwide across the United States. This means that compounding pharmacies, medical suppliers, and potentially other distributors throughout all 50 states may have received inventory from this specific lot. Because the product is an intermediate ingredient for prescription compounding, it may have been incorporated into various custom formulations before reaching the end patient. The recall was officially announced on August 3, 2026. It is important to understand that while the distribution was national, the primary recipients of this product are professional entities in the healthcare supply chain rather than retail drugstores selling over-the-counter goods.
Understanding exactly what was recalled helps clarify who needs to take action. Since this item is labeled strictly for prescription compounding, it is unlikely to be found in a typical household medicine cabinet. However, anyone involved in the preparation of custom compounded medications using Tadalafil from this specific manufacturer and lot must verify their inventory immediately. The recall covers the physical bags containing the 100-gram quantity of the drug substance. If you are a patient who has received a compounded medication recently, it is advisable to contact your pharmacist to verify whether the ingredients used came from this specific recalled lot, as they will have the detailed records of their suppliers.
The hazard, explained
At first glance, the term "CGMP deviations" might sound like bureaucratic jargon reserved for factory inspectors and quality assurance managers. However, in the world of pharmaceuticals, these three letters represent a critical breach of trust between manufacturers and patients. CGMP stands for Current Good Manufacturing Practices, a rigorous set of standards established by the U.S. Food and Drug Administration (FDA) to ensure that drugs are consistently produced and controlled according to quality standards. When an agency like the FDA notes "CGMP deviations" during an inspection, it is not merely citing a paperwork error; it is identifying fundamental failures in the processes designed to keep medication safe, pure, and effective.
The specific hazard here stems from the fact that Tadalafil USP, a drug used to treat erectile dysfunction and pulmonary arterial hypertension, was manufactured under conditions that failed to meet these mandatory controls. While the recall notice does not specify exactly which steps were neglected, CGMP failures generally involve lapses in environmental controls, inadequate sterilization procedures, improper documentation of mixing processes, or the use of contaminated equipment. For a substance like Tadalafil, which is often used in compounding pharmacies to create customized dosages for individual patients, the integrity of the raw material is paramount. If the manufacturing environment allowed for contamination, or if the chemical synthesis was not tightly controlled, the resulting powder may contain impurities, incorrect concentrations, or microbial contaminants that are invisible to the naked eye.
So, how does this translate to physical harm? The risk lies in the unpredictability of the final product. When a compounding pharmacist receives a bag of Tadalafil USP that was produced with CGMP deviations, they cannot verify its purity or potency. If the drug is contaminated, patients may experience adverse reactions ranging from mild allergic responses to severe infections or toxic effects. If the chemical composition is inconsistent, some doses may be too weak to provide therapeutic benefit, while others could be dangerously potent. For a medication that affects blood pressure and cardiovascular function, such variability is particularly dangerous. It can lead to fainting, heart complications, or a complete lack of treatment efficacy when the patient most needs it.
Furthermore, because this product was labeled "For Prescription Compounding Only," it was not intended for direct consumer use but rather as an ingredient for pharmacists to mix into final formulations. This adds a layer of complexity to the hazard. The deviation occurred at the bulk manufacturing stage in Gujarat, India, meaning the problem is embedded in the foundation of the drug before it ever reaches a pharmacy shelf. Consumers relying on compounded Tadalafil derived from this specific lot (TLF2506001) are unknowingly exposed to these latent risks. The danger is not always immediate or obvious; it can manifest days or weeks later as unexplained symptoms, making it difficult to trace the cause back to a manufacturing flaw rather than a personal health issue.
It is important to understand that CGMP is not just a suggestion; it is the primary defense against medical disasters. History has shown us that when these standards are ignored, the results can be catastrophic, from contaminated batches causing widespread illness to incorrect dosages leading to fatalities. In this case, the FDA’s classification of this recall as Class II indicates that use of or exposure to the violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. While it may not be an immediate life-threatening emergency for every user, the underlying uncertainty is significant. You cannot see, smell, or taste a CGMP failure. The only way to eliminate the risk is to assume that any product from this batch has been compromised by the breakdown in quality controls and to remove it from your system entirely.
Who is most at risk
To understand who faces potential exposure in this specific recall, it is essential to first look at the nature of the product involved. Shoolin Pharma Chem LLP’s Tadalafil USP is not a standard over-the-counter medication that you might find on a pharmacy shelf ready for immediate use. The labeling explicitly designates the substance as "For Prescription Compounding Only." This distinction is critical because it means the raw powder is intended to be purchased by licensed pharmacists or compounding pharmacies, who then mix and prepare individual doses for patients based on a specific doctor’s prescription. Therefore, the primary group at risk consists of individuals who have recently visited a compounding pharmacy and received a customized medication containing this specific ingredient.
The individuals most likely to be affected are those with chronic health conditions that require tailored dosage regimens. Tadalafil is commonly prescribed for erectile dysfunction and benign prostatic hyperplasia (BPH). Patients managing these conditions often rely on compounding pharmacies to create doses that differ from standard commercial tablet strengths, allowing for more precise control over their treatment. If you have recently filled a prescription for compounded tadalafil, particularly from a pharmacy that sources its active ingredients from international suppliers like Shoolin Pharma Chem LLP, you fall into the primary risk category. The distribution pattern indicates these materials were sent nationwide across the United States, so geographic location does not limit your potential exposure.
While the recall classification is Class II, indicating that use of or exposure to the product may cause temporary health problems or pose a slight threat of a serious nature, the specific hazard here is adherence to Current Good Manufacturing Practices (CGMP). CGMP deviations do not necessarily mean the drug is contaminated with poison, but they suggest that the manufacturing environment or processes did not meet federal quality standards. For most healthy adults, this might result in inconsistent potency—meaning the medication could be weaker or stronger than labeled—or potential impurities from poor environmental controls. However, certain populations are more vulnerable to these variations. Elderly patients, who often take multiple medications and may have reduced kidney or liver function, are at higher risk because their bodies process drugs differently. Any deviation in purity or dosage consistency can lead to unexpected side effects or reduced therapeutic benefit.
Additionally, patients with cardiovascular issues must be cautious. Tadalafil interacts with blood pressure and heart function. If the compounding process failed due to CGMP deviations, the uniformity of the dose could be compromised. For someone whose health is tightly managed by a cardiologist, even small variations in drug concentration can disrupt their treatment plan. While children are not typically prescribed tadalafil for these common indications, any household where a compounded medication is stored poses a risk of accidental ingestion if the raw powder or final compounded product is not securely kept away from minors. Ultimately, the risk is not about panic, but about verification. If you have been using compounded tadalafil recently, especially from a pharmacy that may have used this specific lot (TLF2506001), you should contact your pharmacist to verify if they received this material from Shoolin Pharma Chem LLP before continuing use.
How to tell if you have the recalled item
Identifying whether a product is part of this specific recall requires careful attention to several distinct details on the packaging and documentation. Because this recall involves a pharmaceutical ingredient intended for compounding rather than a finished consumer drug, the identification process relies heavily on verifying manufacturer information, lot numbers, and physical specifications. If you are a pharmacy professional or a healthcare provider handling bulk materials, you must cross-reference your inventory against the official recall data to ensure no affected units remain in circulation.
First, verify the manufacturer and brand name. The recalled product is distributed under the brand Shoolin Pharma Chem. Specifically, look for the company name Shoolin Pharma Chem LLP on any labels, certificates of analysis, or shipping documentation. This entity is located in Kadi, Mahesania, Gujarat, India. If your supplier lists a different manufacturer, this specific recall does not apply to you, though it is always wise to verify the authenticity of any pharmaceutical ingredient from international sources.
Next, examine the product description and chemical identifiers. The recalled item is TADALAFIL USP. It is crucial to check the quantity format; this recall specifically affects bags containing 0.100 KG (or 0.1KG/100gm) of the substance. Ensure the label clearly states "For Prescription Compounding Only" and indicates it is "Rx only". You should also look for the National Drug Code (NDC) 85702-002-02 and the CAS number 1715996-29-5. These codes are unique identifiers that help distinguish this specific batch from other batches of Tadalafil produced by different manufacturers or in different quantities.
The most critical step is checking the lot number. The recall applies exclusively to items with the lot number TLF2506001. If your inventory contains Tadalafil bags with a different lot number, they are not part of this specific FDA action. Additionally, note the expiration date listed on the packaging, which is May 31, 2028, for the affected lots. Since the product was distributed nationwide across the USA, it could be in any pharmacy or compounding facility that received shipments from Shoolin Pharma Chem LLP. If you cannot locate the lot number on the outer packaging, consult your incoming shipment records or invoices, as these documents should explicitly list the lot and NDC information for compliance purposes.
What to do — step by step
If you are a pharmacy or healthcare professional who has received this specific batch of Tadalafil from Shoolin Pharma Chem LLP, the first and most critical action is to immediately stop using, dispensing, or distributing the product. The FDA has classified this recall as a Class II event, which indicates that while the situation may not be life-threatening in every instance, the deviation from Current Good Manufacturing Practice (CGMP) standards poses a serious risk to health or safety if the product is used. Because the recall stems from CGMP deviations noted during an FDA inspection, there is no guarantee that the chemical composition, purity, or potency of the Tadalafil USP meets the strict regulatory requirements for pharmaceutical ingredients. Using it could lead to unpredictable therapeutic outcomes or exposure to contaminants. Therefore, treating this inventory as compromised is not just a legal obligation but a fundamental patient safety imperative.
Next, you must isolate the affected product physically. Locate Lot number TLF2506001, which expires on May 31, 2028, and is packaged in 0.1 KG (100gm) bags marked with NDC 85702-002-02. Quarantine these items in a secure area separate from your active pharmaceutical inventory to prevent any accidental mix-ups or inadvertent dispensing to patients. Clearly label the quarantined stock with "RECALLED - DO NOT USE" to ensure that any staff member handling the materials understands the status of the product. This physical separation is vital because Tadalafil is a potent medication often used for treating erectile dysfunction and pulmonary arterial hypertension; even minor variations in quality control can have significant clinical implications for patients relying on consistent dosing.
Regarding the specific remedy, the official recall notice does not state whether you should return the product to Shoolin Pharma Chem LLP, destroy it, or request a refund. This is an important detail to note honestly: the agency has not provided explicit instructions on the disposition of the stock in this particular alert. Because the remedy is not stated, you must take proactive steps to clarify how to handle the inventory. Contact Shoolin Pharma Chem LLP directly at their facility in Kadi, Mahesania, Gujarat, India, or reach out to your immediate supplier and distributor. Ask them specifically for instructions on whether they are collecting the goods or if they have authorized destruction protocols. Document all communications regarding this product, including dates, times, and the names of representatives you speak with.
Finally, notify any customers or healthcare facilities that may have already received this lot before it was pulled from circulation. If you have dispensed or sold this specific NDC and Lot combination, you need to trace those records immediately. Contact those parties to inform them of the recall and advise them to cease use of the product. While the hazard is related to manufacturing compliance rather than a reported adverse event, the uncertainty surrounding the quality control deviations warrants caution. By taking these deliberate steps—stopping use, isolating stock, seeking clear disposal instructions, and notifying downstream recipients—you ensure that you are acting responsibly and prioritizing public health during this regulatory issue.
Your refund, repair, or replacement options
When you encounter a Class II drug recall, the immediate question often revolves around financial restitution or product replacement. In this specific instance involving Shoolin Pharma Chem LLP’s TADALAFIL USP, the official FDA recall documentation does not explicitly state the remedy. This means there is no publicly confirmed information regarding whether you will receive a refund, a direct exchange for a new batch, or a repair (though repairs are virtually non-existent for pharmaceutical compounds). It is important to understand that in the world of regulated drug recalls, particularly those classified as Class II, the primary focus is almost always on removing the product from the supply chain to ensure patient safety rather than facilitating consumer transactions. Because the recall notice does not provide specific instructions for consumers regarding financial compensation or replacement protocols, you should not assume that a standard retail return policy applies here.
Since this product is labeled "For Prescription Compounding Only" and is distributed as an active pharmaceutical ingredient (API) rather than a finished, over-the-counter medication, the typical consumer refund channels are likely not applicable. You probably did not purchase this item directly from a store shelf; instead, it was intended for use by licensed pharmacists or compounding pharmacies to create custom prescriptions. Therefore, if you are a patient who believes you may have received medication compounded with this specific lot (TLF2506001), your recourse is not through a customer service call center for a refund. Instead, you must contact the healthcare provider or pharmacy that dispensed the medication to you. They are the entities responsible for managing the inventory and will be the ones to coordinate any necessary steps with Shoolin Pharma Chem LLP or their distributors.
If you are a business entity, such as a compounding pharmacy or distributor, that holds this product in stock, your options are strictly defined by standard recall procedures for Class II violations involving Current Good Manufacturing Practice (CGMP) deviations. You should immediately isolate the product to prevent any further distribution or use. Because the remedy is not stated, you must reach out to the manufacturer directly at Shoolin Pharma Chem LLP to inquire about their specific return authorization process. They may offer a credit against future orders, a full refund upon verified return of the goods, or other negotiated terms, but these details are private to that business relationship and are not part of the public FDA alert.
In summary, because the official record is silent on the remedy, do not attempt to claim money back through general consumer protection agencies for this specific item. Your path forward depends entirely on your role in the supply chain. For patients, consult your pharmacist or doctor immediately to discuss alternative treatments and ensure no further doses are taken. For businesses, initiate direct contact with the manufacturer to resolve the logistical aspects of the return. Always prioritize your health and compliance over financial recovery in these scenarios.
What can happen if you ignore it
When a product recall is issued due to Current Good Manufacturing Practice (CGMP) deviations, the immediate concern isn't always a sudden, visible defect like a cracked casing or a broken wire. Instead, the risk is often invisible, embedded in the very structure of how the medication was created. In this specific case involving Tadalafil USP from Shoolin Pharma Chem LLP, the FDA identified deviations during an inspection. While the recall classification is Class II—meaning it is unlikely to cause serious adverse health consequences or death—the term "deviation" carries significant weight in pharmaceutical safety. Ignoring a recall of this nature means continuing to use a substance that has not met the rigorous federal standards required to ensure its purity, strength, quality, and identity.
To understand why this matters, it helps to look at what CGMP standards are designed to protect against. These regulations are the backbone of drug safety, ensuring that every batch of medication is consistent with previous batches and free from contamination, mix-ups, or labeling errors. When a manufacturer deviates from these practices, the integrity of the active ingredient—Tadalafil, which is used to treat conditions like erectile dysfunction and pulmonary arterial hypertension—can be compromised. This does not necessarily mean the drug is poisoned or toxic in a traditional sense, but it does raise the possibility that the dosage may be inconsistent. You might receive a tablet with less active ingredient than labeled, rendering it ineffective for your condition, or potentially more, which could lead to unexpected side effects such as dangerous drops in blood pressure, vision changes, or prolonged erections.
Furthermore, CGMP violations often point to broader issues in the production environment, such as improper storage conditions, cross-contamination with other substances, or inadequate testing protocols. If the facility failed to maintain proper environmental controls, the chemical stability of the Tadalafil could be degraded over time, even before the expiration date of May 31, 2028. Using a chemically unstable medication can lead to unpredictable therapeutic outcomes. For individuals relying on this drug for daily management of their health, an inconsistent supply from a recalled lot creates a gap in care that can exacerbate underlying medical conditions.
It is also important to consider the context of distribution. This product was distributed nationwide and is labeled "For Prescription Compounding Only." This means it is an intermediate ingredient used by pharmacies to create custom doses for patients. If you are receiving compounded medication from a pharmacy that had this specific lot (TLF2506001) in stock, ignoring the recall means you are unknowingly using a base ingredient that has not been verified as meeting FDA standards. The consequence is a lack of assurance that what you are taking is exactly what was prescribed. In the world of medicine, trust in the supply chain is paramount. By choosing to ignore the recall, you are accepting an unverified variable into your healthcare regimen, potentially trading your known health status for an uncertain one without any compensatory benefit.
Staying safe: broader tips
When dealing with pharmaceutical products, particularly those intended for compounding rather than direct retail sale, maintaining a vigilant approach to your medication supply chain is one of the most effective ways to protect your health. While specific recalls like the recent FDA action involving Shoolin Pharma Chem LLP highlight the importance of regulatory oversight, there are broader habits you can adopt to ensure the safety and integrity of all medications you or your healthcare providers handle.
First, stay informed by regularly checking official government resources. The U.S. Food and Drug Administration (FDA) maintains a comprehensive database of drug recalls that is updated frequently. Subscribing to FDA email alerts or visiting their website periodically allows you to be among the first to know if a specific manufacturer or batch has been flagged for issues such as Current Good Manufacturing Practice (CGMP) deviations. These deviations can range from minor documentation errors to significant contamination risks, and knowing what to look for empowers you to take immediate action before any harm occurs.
Second, foster open communication with your healthcare providers and pharmacists. If you receive medication that appears unusual in packaging, labeling, or physical appearance, do not hesitate to ask questions. For compounded drugs, which are customized for individual patients, it is especially important to verify the source of the active pharmaceutical ingredients. Ensure that your compounding pharmacy uses reputable suppliers who adhere strictly to quality standards. If a recall notice mentions a specific lot number or National Drug Code (NDC), share this information directly with your pharmacist so they can cross-reference their inventory against the alert.
Finally, practice safe storage and disposal habits. Medications should always be stored in their original containers, away from moisture, heat, and direct sunlight, to maintain their chemical stability until dispensed. If you ever suspect a product’s integrity is compromised, or if you have old medications that are no longer needed, dispose of them properly through drug take-back programs rather than throwing them in the trash or flushing them down the toilet. This not only prevents accidental ingestion but also protects the environment from pharmaceutical contamination. By combining these general safety practices with awareness of specific recall notices, you create a robust layer of protection for your well-being.